SAB4700240
Monoclonal Anti-CD52 antibody produced in mouse
clone HI186, purified immunoglobulin, buffered aqueous solution
Synonym(s):
Anti-CAMPATH-1
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
NACRES:
NA.41
clone:
HI186, monoclonal
application:
FACS
species reactivity:
human
technique(s):
flow cytometry: suitable
citations:
1
Recommended Products
biological source
mouse
Quality Level
conjugate
unconjugated
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
HI186, monoclonal
form
buffered aqueous solution
species reactivity
human
concentration
1 mg/mL
technique(s)
flow cytometry: suitable
isotype
IgG2b
NCBI accession no.
UniProt accession no.
shipped in
wet ice
storage temp.
2-8°C
target post-translational modification
unmodified
Gene Information
human ... CD52(1043)
General description
The antibody HI186 reacts with CD52 (CAMPATH-1), a 21-28 kDa glycoprotein containing a large N-linked carbohydrate moiety; mature CD52 molecule is actually much smaller (approx. 8-9 kDa). CD52 is expressed at high levels on lymphocytes, monocytes/macrophages and in male reproductive tract.
Immunogen
Human tonsil
Application
The reagent is designed for Flow Cytometry analysis. Suggested working dilution for Flow Cytometry is 2 μg/mL of sample. Indicated dilution is recommended starting point for use of this product. Working concentrations should be determined by the investigator.
Features and Benefits
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
Physical form
Solution in phosphate buffered saline, pH 7.4, with 15 mM sodium azide.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
10 - Combustible liquids
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
T Nikolic et al.
Genes and immunity, 18(3), 176-183 (2017-08-11)
Tolerogenic dendritic cells (tolDCs) are assessed as immunomodulatory adjuvants to regulate autoimmunity. The underlying gene expression endorsing their regulatory features remains ill-defined. Using deep mRNA sequencing, we compared transcriptomes of 1,25-dihydroxyvitaminD
Sarah K Tasian et al.
Blood, 129(17), 2395-2407 (2017-03-02)
We and others previously reported potent antileukemia efficacy of CD123-redirected chimeric antigen receptor (CAR) T cells in preclinical human acute myeloid leukemia (AML) models at the cost of severe hematologic toxicity. This observation raises concern for potential myeloablation in patients
Gaetano Lucisano et al.
Transplant international : official journal of the European Society for Organ Transplantation, 32(9), 949-959 (2019-04-14)
There are conflicting data about the role of transplant nephrectomy and immunosuppression withdrawal on the development of allosensitization and the impact on re-transplantation. We divided 109 first graft recipients into two groups according to whether they underwent nephrectomy (NX+, n = 61)
Jianhui Liu et al.
Biological & pharmaceutical bulletin, 41(9), 1423-1429 (2018-06-15)
Recent studies suggested that excessive T helper (Th)1/17 cells concomitant with regulatory T cell deficiency might play important roles in Crohn's disease. Anti-cluster of differentiation 52 (CD52) monoclonal antibody (mAb), which aims on CD52 antigen on mature immunocytes, has both
Carlos Cuesta-Mateos et al.
Biomarker research, 8, 54-54 (2020-10-29)
T-cell prolymphocytic leukemia (T-PLL) is a poor prognostic disease with very limited options of efficient therapies. Most patients are refractory to chemotherapies and despite high response rates after alemtuzumab, virtually all patients relapse. Therefore, there is an unmet medical need
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service